GSK’s Ojjaara approved by FDA for patients with blood cancer and anemia 18-Sep-2023 By Jonathan Smith The small molecule drug Ojjaara (momelotinib), developed by GlaxoSmithKline, has become the first U.S. Food and Drug Administration (FDA)-approved treatment for patients with the blood cancer myelofibrosis and anemia.